Open an account

ProQR Therapeutics NV

PRQR · NASDAQ

$1.38+$0.07 (+5.34%)TodayMarket closed ·
Prev close $1.31

About PRQR

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 187 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).

Employees
187
Headquarters
Leiden, Zuid-Holland
Listed
Sep 18, 2014
Sector
Health Care
Industry
Biotechnology
Website
proqr.com

PRQR key statistics

Market cap
194.75M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
836.87K
Volume
938.62K
Open price
$1.31
High today
$1.38
Low today
$1.31
52 Week high
$3.10
52 Week low
$1.30

ProQR Therapeutics NV (PRQR) at a glance

ProQR Therapeutics NV (PRQR) last traded at $1.38, with a market cap of 194.75M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.31 and $1.38. The current price is 5.3% above the day's low and 0.0% below its high.

Volume so far is 938.62K shares, in line with the average of 836.87K shares a day.

Over the past year ProQR Therapeutics NV has ranged from $1.30 to $3.10, and now sits 4% of the way up that range.

ProQR Therapeutics NV met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.1163.

The average analyst price target is $8.67, 528.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 12 analystsAvg $8.67
Low
$3.03
Now
$1.38
High
$15.75

PRQR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 12.4% on average.

  1. Q3 FY24: reported -$0.10 per share against an estimate of -$0.1076
  2. Q4 FY24: reported -$0.0936 per share against an estimate of -$0.0939
  3. Q1 FY25: reported -$0.10 per share against an estimate of -$0.0943
  4. Q2 FY25: reported -$0.12 per share against an estimate of -$0.0836
  5. Q3 FY25: reported -$0.10 per share against an estimate of -$0.105
  6. Q4 FY25: reported -$0.084 per share against an estimate of -$0.1035
  7. Q1 FY26: reported -$0.13 per share against an estimate of -$0.122
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.1163

PRQR news

  • Vandana Singh

    Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Avi Kapoor

    This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

  • Avi Kapoor

    CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

  • Avi Kapoor

    Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as ProQR Therapeutics NV

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.